PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Technion Research and Development Foundation, Ltd.	06/27/2011

RECEIVING PARTY DATA

Name:	Teva Pharmaceutical Industries, Ltd.
Street Address:	5 Basel Street
Internal Address:	P.O. Box 3190
City:	Petach-Tikva
State/Country:	ISRAEL
Postal Code:	49131

PROPERTY NUMBERS Total: 1

Property Type	Number
Patent Number:	5576353

CORRESPONDENCE DATA

Fax Number: (212)391-0525

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 212-278-0400

Email: mlin@cooperdunham.com
Correspondent Name: Cooper & Dunham LLP
Address Line 1: 30 Rockefeller Plaza

Address Line 4: New York, NEW YORK 10112

NAME OF SUBMITTER: Michael Lin

Total Attachments: 5

source=110812_2609_43017_Signed_Assignment_Page1_ML#page1.tif source=110812_2609_43017_Signed_Assignment_Page2_ML#page1.tif source=110812_2609_43017_Signed_Assignment_Page3_ML#page1.tif source=110812_2609_43017_Signed_Assignment_Page4_ML#page1.tif source=110812_2609_43017_Signed_Assignment_Page5_ML#page1.tif

PATENT

REEL: 026745 FRAME: 0446

CH \$40.00 557

PATENT RIGHTS ASSIGNMENT

This Patent Rights Assignment (this "Assignment") is made effective October 1, 2010, by and between the Technion Research & Development Foundation, Ltd., ("Assignor"), and Teva Pharmaceutical Industries Ltd. ("Assignee").

WHEREAS, Assignor possesses certain rights in and to the Patent Applications and Patents set forth in <u>Schedule A</u> and Supplementary Protection Certificates (SPCs) set forth in <u>Schedule B</u>, each attached hereto and incorporated herein by reference (collectively, the "Assigned Patents"); and

WHEREAS, Assignor now wishes to assign all of its right, title and interest in and to the Assigned Patents to Assignee, and Assignee desires to acquire all of Assignor's right, title and interest in and to the Assigned Patents from Assignor;

NOW, THEREFORE, in consideration of Ten Thousand Dollars (10,000 USD) and for other good and valid consideration (including the costs of recordation of assignment), the receipt and sufficiency of which is hereby acknowledged:

Assignor does hereby assign, convey and transfer unto Assignee and its successors, assigns, and legal representatives, Assignor's entire right, title and interest in and to the Assigned Patents (including any and all patent term extensions, reissues, reexaminations, extensions or supplementations thereof, and every priority right) to the full end of the term for which said rights have been granted as fully and entirely as the same would have been held by Assignor had this assignment not been made; and Assignor hereby conveys all of its rights in and to the Assigned Patents arising under or pursuant to any and all laws relating to the protection of patent rights, including but not limited to any cause(s) of action and damages accruing prior to this Assignment.

Assignor hereby further agrees for itself and its successors, assigns, agents, and legal representatives to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the rights in the Assigned Patents to Assignee, its successors, assigns, and legal representatives, and generally do everything possible to aid Assignee, its successors, assigns and legal representatives to obtain, record, maintain, and enforce full protection for the Assigned Patents in all countries, but in each instance at Assignee's expense.

Assignor hereby warrants that it has not conveyed to anyone other than Assignee any rights in the Assigned Patents or any license to use the same or to make, use or sell anything embodying or utilizing any of the Assigned Patents, and that it has good right to assign the Assigned Patents to Assignee without encumbrance.

Assignor does hereby authorize all proper governmental authorities to record this Assignment of the Assigned Patents to show that all right, title and interest in the Assigned Patents reside with the Assignee, its successors, assigns, or legal representatives in accordance with the terms of this Assignment.

Page 1 of 2

2609/43017
Patent Rights Assignment

IN WITNESS WHEREOF, Assignor has caused this Assignment to be executed by its duly authorized representative as of the date first written above.

Technion Research and Development Foundation Ltd. By: Oll Development Foundation Ltd. Printed Name: Old Shared Tel: 04-8325 PAGE: MANAGER Title: MANAGING DIACCTOR Tel: 04-8325 PAGE: MANAGER Date: Our 27, 20// Date: Signature Tel: 04-8325 PAGE: MANAGER Witness: Witness: Fignature Tel: 04-8325 PAGE: MANAGER Witness: Fignature Tel: 04-8325 PAGE: MAN	Date: June 27, 2011 Witness: [signature] OUGCAS [printed name] CITY [address] DO. SENATE BLOG. HAIFA J2000 ZSNAEL Date: June 27, 2011 Witness: [signature] ACFLEO DouGCAS [printed name] TECHNION CITY [address] SENATE BLOG. HAIFA J2000 ZSNAEL Dutical Industries Ltd. (Assignee) hereby accepts this assignment. By: Printed Name:	Technion Research and	d Developm rati faнцфаф	SESTEN SESSE SESSE		
Title: MANAGING DIRECTOR TET: 04-8325 FIRE: MANAGER Date: Date: Date: June 27, 201 Witness: Witness: [signature] FECHNION CITY [address] SENATE BLOG. [address]	Signature Date: June 27, 2011 Witness: Isignature Signature Signature Technical City Sanate Scot Scot Scot Scot Scot Scot Scot Scot	malal	() Development Fo	oundation Ltd		
Title: MANAGING DIRECTOR TET: 04-8325 FIRE: MANAGER Date: Date: Date: June 27, 201 Witness: Witness: [signature] FECHNION CITY [address] SENATE BLOG. [address]	Signature Date: June 27, 2011 Witness: [signature] Witness: [signature] ACTAIN DOUBLAS [printed name] TECHNION CITY [address] SENATE BLOG-HAIFA J2000 ZSNAEL Sudical Industries Ltd. (Assignee) hereby accepts this assignment.	By: 0 000	Technion City Hai	if a 32000 . I		
Date:	Date: Signature Witness: Signature	Printed Name: OVED SHAUETTON CRY Halla Printed Name BONJAMIN SOFTEN				
Witness: [signature] [signature] [signature] [signature] [printed name] [printed name] [address] SENATE BUDG. Witness: [signature] [printed name] [address] SENATE BUDG.	Witness: [signature] [signature] [signature] [signature] [printed name] [signature] [printed name] [address] [ad			323 Bidle: MANHORIC		
[signature] ALFRIED DOUGLAS [printed name] TECHNION CITY [address] SENATE BLDG. [signature] [signature] ALFRIED DOUGLAS [printed name] TECHNION CITY [address] SENATE BLDG.	[signature] Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signature Signatu		Qure 27,2011	7		
FERSO DOUGLAS [printed name] TECHNION CITY [address] SENATE BLOG. [printed name] SENATE BLOG.	DUCCAS [printed name] ACTURD DOUGLAS [printed name] TECHNION CITY [address] SENATE BLOG- HAIFA J2008 ZSAAEL Dutical Industries Ltd. (Assignee) hereby accepts this assignment. By: Printed Name:	Witness:				
TECHNION CITY [address] SENATE BLOG. [address]	TECHNION CITY [address] SENATE BLOG. HAIFA J2008 ZSAAEL sutical Industries Ltd. (Assignee) hereby accepts this assignment. By: Printed Name:			signature		
TECHNION CITY [address] SENATE BLDG. HAIFA 32000 ISPAEL HAIFA 32000 ISPAEL HAIFA 32000 ISPAEL	By: Printed Name:	ALFRED DOUGLA	[printed name]			
SENATE BLOG. SENATE BLOG. HAIFA 32000 ISRAEL HAIFA 32000 ISRAEL	By: Printed Name:	Torrellian CITA	[address]			
MAIFA 32000 ISRAEL HAIFA 32000 ISRAEL	By: Printed Name:	TECAPION CITY				
	By: Printed Name:	SENATE BLDG.	mmutanianiani			
Teva Pharmaceutical Industries Ltd. (Assignee) hereby accepts this assignment. By:	Printed Name:	MAIFA 32000 I	SPAEL	HAIFA 32000 ZSNAEL		
Printed Name: Printed Name:		<i>HAIFA 32000 I</i> Teva Pharmaceutical I	ndustries Ltd. (Assignee)	HAIFA 12000 ISAAEL hereby accepts this assignment.	-	
	1 1116.	<i>HAIFA 32000 I</i> Teva Pharmaceutical I By:	ndustries Ltd. (Assignee)	HAIFA J2000 ZSAAEL hereby accepts this assignment. By:		
	Date'	<i>HAIPA 32000 I</i> Teva Pharmaceutical I By: _ Printed Name:	ndustries Ltd. (Assignee)	HAIFA J2000 ZSAAEL hereby accepts this assignment. By: Printed Name:		
Title: Title:	Date.	HAIFA 32000 I Teva Pharmaceutical I By: Printed Name: Title:	ndustries Ltd. (Assignee)	HAIFA J2000 ZSAAEL hereby accepts this assignment. By: Printed Name: Title:		
		HAWA 32000 Teva Pharmaceutical I By: _ Printed Name: _ Title: _ Date: _	ndustries Ltd. (Assignee)	HAIFA J2000 ZSAAEL hereby accepts this assignment. By: Printed Name: Title: Date:		
Title:	Witness:	HAWA 32000 Teva Pharmaceutical I By: _ Printed Name: _ Title: _ Date: _	ndustries Ltd. (Assignee)	hereby accepts this assignment. By: Printed Name: Title: Date: Witness:		
Title: Title: Date: Date: Witness: Witness:	Witness: [signature]	HAWA 32000 Teva Pharmaceutical I By: _ Printed Name: _ Title: _ Date: _	ndustries Ltd. (Assignee) [signature]	hereby accepts this assignment. By: Printed Name: Title: Date: Witness: [signature]		
itle:Title:	Lute.	AAIFA 32000 I eva Pharmaceutical I y:_ rinted Name: itle:	ndustries Ltd. (Assignee)	HAIFA J2000 ZSAAEL hereby accepts this assignment. By: Printed Name: Title:		
Title:		HAIFA 32000 I Teva Pharmaceutical I By: _ Printed Name: _ Title: _ Date: _	ndustries Ltd. (Assignee)	HAIFA J2000 ZSAAEL hereby accepts this assignment. By: Printed Name: Title: Date:		
Title: Title: Date: Date: Witness: Witness:	Witness:	HAWA 32000 Teva Pharmaceutical I By: _ Printed Name: _ Title: _ Date: _	ndustries Ltd. (Assignee)	hereby accepts this assignment. By: Printed Name: Title: Date: Witness:		
Title: Title: Date: Date: Witness: Witness: [signature] [signature]	Witness:[signature][signature]	HAWA 32000 Teva Pharmaceutical I By: _ Printed Name: _ Title: _ Date: _	ndustries Ltd. (Assignee) [signature]	hereby accepts this assignment. By: Printed Name: Title: Date: Witness: [signature]		
Title: Title: Date: Date: Witness: Witness: [signature] [signature]	Witness: [signature] [signature] [printed name] [printed name]	HAWA 32000 Teva Pharmaceutical I By: _ Printed Name: _ Title: _ Date: _	ndustries Ltd. (Assignee) [signature] [printed name]	hereby accepts this assignment. By: Printed Name: Title: Date: Witness: [signature] [printed name]		

IN WITNESS WHEREOF, Assignor has caused this Assignment to be executed by its duly authorized representative as of the date first written above.

Technion Research and Development Foundation Ltd. (Assignor)

By:			
Printed Name:		Printed Name:	
		Title:	
Date:		Date:	
Witness:		Witness:	
	[signature]		[signature]
	[printed name]		[printed name]
	[address]		[addraga]
	-		
	ala kannanda 6 gali kindan iliyaka kanda oo ka n goo dalamin oo kannan oo ka	And the restrict of the control of t	onan-manan-man-magain-m
By: Printed Name: _ Title:	Conoral Detail O		on Hausdorff, Ph.D. te General Palent Course
Date:	1, June 22, 2011	Date:	June 22, 2011
Witness:	1/0	Witness:	1
Ulura,	[signature]	Jun St	[signature]
VIVIAN S	7	Vivian Sa	ha [printed name]
5 Basel	S+ [address]	5 Basel S	,
Peta	ch Tihva Jssael	Petach Tiku	
,	Israel		shael

Schedule A (Patent Applications and Patents) to Asssignment from Technion Research and Development Foundation Ltd. to Teva Pharmaceutical Industries Ltd.

Country	Application/Patent No.	Filing/Grant Date
US	5,668,181	September 16, 1997
US	5,576,353	November 19, 1996
US	5,599,991	February 4, 1997
US	5,891,923	April 6, 1999
US	5,519,061	May 21, 1996
US	5,744,500	April 28, 1998
US	6,316,504	November 13, 2001
US	6,630,514	October 7, 2003
US	6,956,060	October 18, 2005
Australia	630772	February 26,1993
Austria	0436492	June 8, 1994
Austria	812190	December 8, 2004
Belgium	0436492	June 8, 1994
Belgium	812190	December 8, 2004
Brazil	PI0504448-0	October 24, 2005
Canada	2,031,714	August 25, 1998
Canada	2,174,449	January 16, 2007
Czech Republic	288222	March 13, 2001
Denmark	0436492	June 8, 1994
Denmark	812190	December 8, 2004
Europe	0436492	June 8, 1994
Europe	812190	December 8, 2004
France	0436492	June 8, 1994
France	812190	December 8, 2004
Germany	69102288.7	June 8, 1994
Germany	69434178.9	December 8, 2004
Greece	0436492	June 8, 1994
Greece	3052691	December 8, 2004
Hong Kong	1008017	June 8, 1994
Hungary	215.451	September 6, 2000
Hungary	226.138	April 3, 2008
Ireland	062371	January 9, 1995
Ireland	812190	December 8, 2004
Italy	0436492	June 8, 1994
Italy	812190	December 8, 2004
Japan	2987453	October 8, 1999
Japan	2009-219662	September 24, 2009
Luxembourg	0436492	June 8, 1994
Luxembourg	0 812 190	December 12, 2004
Mexico	236132	April 24, 2006
Monaco	812190	December 8, 2004
Netherlands	0436492	June 8, 1994
	812190	
Netherlands Pertugal	812190	December 8, 2004 December 8, 2004
Portugal Romania	107552	
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	···	December 20, 1993
Russian Federation	2001614	October 30, 1993
Slovak	280,742 90/9997	April 6, 2000
South Africa		October 30, 1991
South Africa	94/8013	July 26, 1995
Spain	2057604	June 8, 1994
Spain	2235170	December 8, 2004
Sweden	0436492	June 8, 1994
Sweden	812190	December 8, 2004
Switzerland	812190	December 8, 2004
United Kingdom	0436492	June 8, 1994
United Kingdom	812190	December 8, 2004

PATENT REEL: 026745 FRAME: 0450

# Schedule B (Supplementary Protection Certificates) to Asssignment from Technion Research and Development Foundation Ltd. to Teva Pharmaceutical Industries Ltd.

Country	SPC No.	Grant Date
Austria	31/2005	April 02, 2007
Belgium	2005C/031	September 1, 2009
Czech Republic	28822/82	August 26, 2005
Denmark	CR 2005 00039	February 11, 2008
France	FR05C0033	August 9, 2005
Germany	12 2005 000 044.2	June 25, 2007
Greece	8000193	N/A
Hungary	S000067	November 20, 2008
Ireland	2005/024	August 23, 2006
Italy	895	October 10, 2005
Luxembourg	91 191	October 10, 2005
Netherlands	300205	January 13, 2006
Portugal	CCP 207	N/A
Romania	c2007 035	N/A
Slovak	DO 32	February 24, 2006
Spain	200500037	N/A
Sweden	0590028-7	July 11, 2006
Switzerland	C00812190/01	August 31, 2007
United Kingdom	SPC/GB05/042	June 12, 2007

**RECORDED: 08/12/2011** 

PATENT REEL: 026745 FRAME: 0451